Schoch J
Fortschr Med. 1975 Jan 23;93(3):133-6.
The clinical effectiveness of an anti-arthrotic drug was investigated in a comparative trial. 106 patients suffering from moderate arthrosis of the knee were placed into two groups in accordance with a random table and treated by intramuscular injection of Arteparon forte or an analogous control product. The criteria of assessment were pain on movement, pain at rest, limitation of active and of passive movement. The number of patients who at the end of treatment and at the time of follow up, three months later, had no or insignificant residual symptoms and signs, were greater in the Arteparon forte group than in the control group. This difference was statistically significant two months after the beginning of treatment for the criterion pain at rest, and five months after beginning of treatment for all criteria. A global assessment of the results was carried out according to the number of pronouncedly improved criteria in the individual patients. According to this assessment, the results of treatment at the termination of treatment amounted to 73.6% in the Arteparon forte group and 56.6% in the control group. At the time of follow up the corresponding value of the Arteparon forte group was 68.4%, thus significantly greater than that of the control group (29.4%).